Key result
Current dyslipidemia guidelines lack female-specific risk enhancers to optimize cardiovascular outcomes in women.
Answers are grounded in this paper and cite their sources.
Incorporating a gender perspective into dyslipidemia management, including recognizing female-specific risk enhancers and addressing unique treatment challenges, is essential for improving cardiovascular outcomes in women.
Dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (CVD), yet disparities in diagnosis, treatment, and outcomes between sexes and genders remain. Although low-density lipoprotein (LDL) cholesterol management targets differ slightly across guidelines, they are generally applied uniformly to both men and women, with evidence suggesting comparable therapeutic benefits. However, women tend to develop CVD later in life and widely used risk scores have limited validation in older adults, leaving uncertainty in risk estimation for older women. In younger women, recent guidelines have begun to incorporate female-specific risk enhancers, such as premature menopause, pregnancy complications, and autoimmune diseases, into cardiovascular risk assessment, though comprehensive guidance remains lacking. Across all guidelines, there is universal agreement that statins are generally contraindicated during pregnancy and lactation, with bile acid sequestrants and LDL apheresis recommended as alternative therapies in cases of severe familial hypercholesterolemia. Additional challenges more frequently observed in women include lower treatment adherence, higher rates of statin intolerance, and lifelong cardiovascular risk shaped by hormonal transitions, all of which require greater clinical attention. Future progress will depend on expanding sex-specific evidence, refining risk models, and implementing equitable treatment strategies. Incorporating a gender perspective into dyslipidemia management is essential for improving cardiovascular outcomes in women.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2025) conducted a review in Dyslipidemia. Gender-specific dyslipidemia management was evaluated. Current dyslipidemia guidelines lack comprehensive female-specific guidance, highlighting the need to incorporate gender perspectives and female-specific risk enhancers to improve outcomes in women.
Synapse has enriched 10 related papers. Consider them for comparative context: